secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001193125-25-271006
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics Q3 revenue $84.1M (+17% YoY), raises FY guidance, non-GAAP EPS $0.14
--------------------------------------------------------------------------------

- Revenue $84.1M, up 17% YoY; raised full-year 2025 revenue guidance to $325.0M.
- GAAP net loss $6.6M ($0.21/share); non-GAAP net income $4.5M ($0.14/share).
- Full-year EPS guidance raised: GAAP loss ~($1.70)/share, non-GAAP income $0.30/share.
- Adjusted EBITDA $0.7M; GAAP gross margin 42.2%, non-GAAP 44.3%.
- Cash and short-term investments $787.7M at quarter end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000119312525271006/0001193125-25-271006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000119312525271006/flgt-20251107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-271006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer